A Self-Assembled Coumarin-Anchored Dendrimer for Efficient Gene Delivery and Light-Responsive Drug Delivery

Wang, Hui; Miao, Wujun; Wang, Fei; Cheng, Yiyun

doi:10.1021/acs.biomac.8b00246

Cited by 57 publications

(31 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, lactoferrin (Lf)-bearing DAB dendriplexes showed similar efficacy [64]. Later, coumarin-anchored low-generation dendrimers (G1 PAMAM dendrimers) were established to improve DNA binding and gene delivery [65]. The coumarin moieties endowed these materials with light-responsive drug delivery behaviors, and the drug-loaded nanoparticles exhibited complementary anticancer activity through the codelivery of 5-fluorouracil and pTRAIL.…”

Section: Nonviral Vectorsmentioning

confidence: 99%

TRAIL-based gene delivery and therapeutic strategies

Zhong

Wang

et al. 2019

Acta Pharmacol Sin

View full text Add to dashboard Cite

TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), also known as APO2L, belongs to the tumor necrosis factor family. By binding to the death receptor 4 (DR4) or DR5, TRAIL induces apoptosis of tumor cells without causing side toxicity in normal tissues. In recent years TRAIL-based therapy has attracted great attention for its promise of serving as a cancer drug candidate. However, the treatment efficacy of TRAIL protein was under expectation in the clinical trials because of the short half-life and the resistance of cancer cells. TRAIL gene transfection can produce a "bystander effect" of tumor cell killing and provide a potential solution to TRAIL-based cancer therapy. In this review we focus on TRAIL gene therapy and various design strategies of TRAIL DNA delivery including non-viral vectors and cell-based TRAIL therapy. In order to sensitize the tumor cells to TRAIL-induced apoptosis, combination therapy of TRAIL DNA with other drugs by the codelivery methods for yielding a synergistic antitumor efficacy is summarized. The opportunities and challenges of TRAIL-based gene delivery and therapy are discussed.

show abstract

Section: Nonviral Vectorsmentioning

confidence: 99%

TRAIL-based gene delivery and therapeutic strategies

Zhong

Wang

et al. 2019

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…Cheng and co‐workers recently constructed a nanosystem based on coumarin‐anchored low generation dendrimers, which could self‐assembly into nanostructures in aqueous solution via hydrophobic interactions . 5‐Fluorouracil (5‐Fu) as an anticancer drug and plasmid DNA for encoding tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) were efficiently loaded into the nanostructures.…”

Section: Uv/vis Light Controlled Drug Delivery Systemsmentioning

confidence: 99%

“…Illustration of the drug loading and photoinduced drug release process from the cross‐linked nanoparticles for cancer therapy. Reproduced with permission . Copyright 2018, American Chemical Society.…”

Section: Uv/vis Light Controlled Drug Delivery Systemsmentioning

confidence: 99%

Remote Light‐Responsive Nanocarriers for Controlled Drug Delivery: Advances and Perspectives

Zhao

Wang

et al. 2019

Small

210

137

View full text Add to dashboard Cite

Engineering of smart photoactivated nanomaterials for targeted drug delivery systems (DDS) has recently attracted considerable research interest as light enables precise and accurate controlled release of drug molecules in specific diseased cells and/or tissues in a highly spatial and temporal manner. In general, the development of appropriate light‐triggered DDS relies on processes of photolysis, photoisomerization, photo‐cross‐linking/un‐cross‐linking, and photoreduction, which are normally sensitive to ultraviolet (UV) or visible (Vis) light irradiation. Considering the issues of poor tissue penetration and high phototoxicity of these high‐energy photons of UV/Vis light, recently nanocarriers have been developed based on light‐response to low‐energy photon irradiation, in particular for the light wavelengths located in the near infrared (NIR) range. NIR light‐triggered drug release systems are normally achieved by using two‐photon absorption and photon upconversion processes. Herein, recent advances of light‐responsive nanoplatforms for controlled drug release are reviewed, covering the mechanism of light responsive small molecules and polymers, UV and Vis light responsive nanocarriers, and NIR light responsive nanocarriers. NIR‐light triggered drug delivery by two‐photon excitation and upconversion luminescence strategies is also included. In addition, the challenges and future perspectives for the development of light triggered DDS are highlighted.

show abstract

“…When NIR light was irradiated at the target site, HPPH-liposomes opened the bilayer structure and then released DOX, but when NIR light was off, the stable bilayer structure of HPPH-liposomes was reformed [ 109 ]. Common photolytic functional groups include O -nitrobenzyl derivatives (ONB), anthracene [ 110 ], coumarin esters [ 111 ], arylmethyl [ 112 ] and pyrenylmethyl ester [ 113 ] ( Table 3 ). Among these, O -nitrobenzyl derivatives have been widely used because of their fast photolysis rate and simple synthesis process.…”

Section: Stimulus-responsive Systemsmentioning

confidence: 99%

Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment

Liu

Lovell

Zhang

et al. 2020

IJMS

View full text Add to dashboard Cite

Stimulus-responsive drug delivery systems generally aim to release the active pharmaceutical ingredient (API) in response to specific conditions and have recently been explored for disease treatments. These approaches can also be extended to molecular imaging to report on disease diagnosis and management. The stimuli used for activation are based on differences between the environment of the diseased or targeted sites, and normal tissues. Endogenous stimuli include pH, redox reactions, enzymatic activity, temperature and others. Exogenous site-specific stimuli include the use of magnetic fields, light, ultrasound and others. These endogenous or exogenous stimuli lead to structural changes or cleavage of the cargo carrier, leading to release of the API. A wide variety of stimulus-responsive systems have been developed—responsive to both a single stimulus or multiple stimuli—and represent a theranostic tool for disease treatment. In this review, stimuli commonly used in the development of theranostic nanoplatforms are enumerated. An emphasis on chemical structure and property relationships is provided, aiming to focus on insights for the design of stimulus-responsive delivery systems. Several examples of theranostic applications of these stimulus-responsive nanomedicines are discussed.

show abstract

A Self-Assembled Coumarin-Anchored Dendrimer for Efficient Gene Delivery and Light-Responsive Drug Delivery

Cited by 57 publications

References 61 publications

TRAIL-based gene delivery and therapeutic strategies

TRAIL-based gene delivery and therapeutic strategies

Remote Light‐Responsive Nanocarriers for Controlled Drug Delivery: Advances and Perspectives

Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment

Contact Info

Product

Resources

About